Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 6, pp 975–977 | Cite as

NSAIDs in paediatrics: caution with varicella!

  • L. Durand
  • P. Sachs
  • C. Lemaitre
  • M. Lorrot
  • J. Bassehila
  • O. Bourdon
  • S. Prot-Labarthe
Commentary

Abstract

Anti-inflammatory drugs have been suspected on several occasions to have promoted development of bacterial infection among varicella patients. Some countries have not implemented childhood varicella vaccination. Three cases in our hospital suggested the predisposing role of NSAIDs in varicella patient deterioration. Open access to these drugs widely increases their use and patient information should be continually provided in the medical offices and at dispensing pharmacy counters. Taking account of the benefit/risk balance and applying the simple precautionary principle, it would be appropriate to be cautious about the use of NSAIDs in the paediatric population.

Keywords

Bacterial complications Children Ibuprofen Infection NSAIDs Paediatrics Varicella 

Notes

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Sentinelles network, UMR S 707, Inserm, UPMC, InVs. 2012 Compilation. [cited 2014 Nov 6]. websenti.u707.jussieu.fr/sentiweb/document/2518.
  2. 2.
    Papaloukas O, Giannouli G, Papaevangelou V. Successes and challenges in varicella vaccine. Ther Adv Vaccines. 2014;2(2):39–55.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    ANSM. Fièvre et douleur chez l’enfant atteint de varicelle: l’utilisation d’anti-inflammatoires non stéroïdiens n’est pas recommandée [Internet]. [cited 2014 Nov 6]. http://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/L-utilisation-d-anti-inflammatoires-non-steroidiens-AINS-dans-le-traitement-de-la-fievre-et-ou-de-la-douleur-n-est-pas-recommandee-chez-l-enfant-atteint-de-varicelle.
  4. 4.
    Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40(2):111–8.PubMedGoogle Scholar
  5. 5.
    Kaplan HB, Edelson HS, Korchak HM, Given WP, Abramson S, Weissmann G. Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochem Pharmacol. 1984;33(3):371–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Pontes T, Antunes H. Group A beta-hemolytic streptococcal toxic shock. Acta Med Port. 2004;17(5):395–8.PubMedGoogle Scholar
  7. 7.
    Leroy S, Mosca A, Landre-Peigne C, Cosson M-A, Pons G. Ibuprofen in childhood: evidence-based review of efficacy and safety. Arch Pediatr. 2007;14(5):477–84.CrossRefPubMedGoogle Scholar
  8. 8.
    Zerr DM, Alexander ER, Duchin JS, Koutsky LA, Rubens CE. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics. 1999;103(4 Pt 1):783–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Lesko SM, O’Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107(5):1108–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Legras A, Giraudeau B, Jonville-Bera A-P, et al. A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. Crit Care. 2009;13(2):R43.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis. 1995;21(4):977–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Voiriot G, Dury S, Parrot A, Mayaud C, Fartoukh M. Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest. 2011;139(2):387–94.CrossRefPubMedGoogle Scholar
  13. 13.
    Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol. 2008;65(2):203–9.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Ulinski T, Bensman A. Renal complications of non-steroidal anti-inflammatories. Arch Pediatr. 2004;11(7):885–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Mounier G, Guy C, Berthoux F, Beyens MN, Ratrema M, Ollagnier M. Severe renal adverse events with arylcarboxylic non-steroidal anti-inflammatory drugs: results of a eight-year French national survey. Therapie. 2006;61(3):255–66.CrossRefPubMedGoogle Scholar
  16. 16.
    ANSM. Mise au point sur la prise en charge de la fièvre chez l’enfant [Internet]. [cited 2014 Nov 6]. http://ansm.sante.fr/var/ansm_site/storage/original/application/8a3e72e8fec9c0f68797a73832372321.pdf.

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • L. Durand
    • 1
    • 2
  • P. Sachs
    • 3
  • C. Lemaitre
    • 4
  • M. Lorrot
    • 4
  • J. Bassehila
    • 5
  • O. Bourdon
    • 1
    • 2
    • 6
  • S. Prot-Labarthe
    • 1
    • 2
    • 7
  1. 1.PharmacieHôpital Robert-Debré, APHPParisFrance
  2. 2.Pharmacie CliniqueUniversité Paris Descartes, Sorbonne Paris CitéParisFrance
  3. 3.Réanimation pédiatriqueHôpital Robert-Debré, APHPParisFrance
  4. 4.Pédiatrie GénéraleHôpital Robert-Debré, APHPParisFrance
  5. 5.Service de Pharmacologie Pédiatrique et PharmacogénétiqueHôpital Robert-Debré, APHPParisFrance
  6. 6.Laboratoire Educations et Pratiques de Santé, EA 3412 Université Paris 13, Sorbonne Paris CitéBobignyFrance
  7. 7.INSERM, ECEVE U1123ParisFrance

Personalised recommendations